This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, M.
Right arrow Articles by Dormont, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, M.
Right arrow Articles by Dormont, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 3150-3154, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

PMS-601, a New Platelet-Activating Factor Receptor Antagonist That Inhibits Human Immunodeficiency Virus Replication and Potentiates Zidovudine Activity in Macrophages

M. Martin,1 N. Serradji,2 N. Dereuddre-Bosquet,1,3 G. Le Pavec,1 G. Fichet,1 A. Lamouri,2 F. Heymans,2 J. J. Godfroid,2 P. Clayette,1,3 and D. Dormont1

CEA, Service de Neurovirologie, DSV/DRM, CRSSA, EPHE, Institut Paris-Sud sur les Cytokines, Fontenay aux Roses,1 Université Denis Diderot-Paris VII, Laboratoire de Pharmacochimie Moléculaire, Paris,2 and SPI-BIO, Massy,3 France

Received 19 November 1999/Returned for modification 3 March 2000/Accepted 28 July 2000

We assessed the anti-human immunodeficiency virus (anti-HIV) activity in vitro of new platelet-activating factor (PAF) receptor antagonists, as PAF and viral replication are thought to be involved in HIV neuropathogenesis. We found that PMS-601 inhibited proinflammatory cytokine synthesis and HIV replication in macrophages and potentiated the antiretroviral activity of zidovudine. These results suggest that PMS-601 is of potential value as an adjuvant treatment for HIV infection.

Antimicrobial Agents and Chemotherapy, November 2000, p. 3150-3154, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Dioszeghy, V., Benlhassan-Chahour, K., Delache, B., Dereuddre-Bosquet, N., Aubenque, C., Gras, G., Le Grand, R., Vaslin, B. (2006). Changes in Soluble Factor-Mediated CD8+ Cell-Derived Antiviral Activity in Cynomolgus Macaques Infected with Simian Immunodeficiency Virus SIVmac251: Relationship to Biological Markers of Progression. J. Virol. 80: 236-245 [Abstract] [Full Text]  
  • Pereira, C. F., Paridaen, J. T. M. L., van de Bovenkamp, M., Middel, J., Verhoef, J., Nottet, H. S. L. M. (2003). APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro. J Antimicrob Chemother 51: 1181-1189 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»